ClinicalTrials.gg
CompletedNCT02260557Updated Jun 3, 2026

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Phase 2 interventional study of Selexipag and Placebo in Raynaud's Phenomenon Secondary to Systemic Sclerosis, sponsored by Actelion. Completed at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Scleroderma, Systemic by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Scleroderma, Systemic · Johnson & Johnson.

Started
2014
the only one that year
Phase 2
2 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Scleroderma, Systemic by Johnson & Johnson, this one is the only one that started in 2014, is one of 2 in phase 2, and was the 9th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

None of the 10 studies in Scleroderma, Systemic by Johnson & Johnson is open now. The open studies under Scleroderma, Systemic, anywhere →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Scleroderma, Systemic by Johnson & Johnson as a file.
02

Study summary

The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).

03

Conditions studied

  • Raynaud's Phenomenon Secondary to Systemic Sclerosis

Keywords

  • Systemic Sclerosis
  • Raynaud's Phenomenon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Signed prior to any study-mandated procedure.
  • Male and female subjects aged 18 years and above with a history of recurrent multiple weekly RP attacks secondary to SSc.
  • Women of must agree to use a reliable method of .

Key exclusion criteria:

  • Known moderate or severe hepatic impairment (i.e. C).
  • Known to selexipag or drugs of the same class, or any of their .
  • Subjects who have received prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostenol, iloprost, beraprost) within 3 months prior to the screening visit.
  • Subjects who have received a Phosphodiesterase type 5 (PDE-5) inhibitor within 1 week prior to the screening visit.
  • Any dose change or initiation of any of the following drugs within 1 month prior to the screening visit: Calcium channel blockers, Nitrates or nitric oxide donors, ERA's, Alpha-blockers, Antithrombotic agents, NSAIDs (occasional use allowed), Angiotensin Converting Enzyme (ACE) inhibitors, Beta-blockers, Clonidine, Systemic , Fluoxetine.
  • Severe renal insufficiency (at randomization).
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Selexipag

    Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.

    Drug: Selexipag

  • Experimental
    Placebo

    Placebo matching selexipag tablets is administered according to the same schedule as selexipag

    Drug: Placebo

Interventions

  • Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily

    Also known as: ACT-293987

  • DrugPlacebo

    Placebo matching selexipag 200 μg tablets to be administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Average number of Raynaud's phenomenon (RP) attacks per week during the maintenance treatment period

    The number of RP attacks is determined from daily entries in electronic Diaries (eDiary).

    Time frame: From Day 26 to Day 56 ( +/- 7 days)

Secondary outcomes

  1. Number of patients with treatment-emergent adverse events

    A treatment-emergent adverse event is any adverse event (AE) temporally associated with the use of a study treatment, whether or not considered related to the study treatment, including any abnormalities in ECG parameters, vital signs or laboratory tests

    Time frame: Up to end of study (Day 86 +/- 7 days)

  2. Number of patients with treatment-emergent serious adverse events

    Time frame: Up to end of study (Day 86 +/- 7 days)

Other outcomes

  1. Change from baseline in quality of life (QOL)

    QOL is assessed by the Scleroderma Health Assessment Questionnaire (SHAQ)

    Time frame: At baseline (Day 1) and end of treatment (Day 56 +/- 7 days)

07

Study locations

16 sites
  • Investigator Site
    Grenoble, 38043, France
  • Investigator Site
    Lille, 59037, France
  • Investigator Site
    Nantes, 44093, France
  • Investigator Site
    Paris, 75679, France
  • Investigator Site
    Strasbourg, 67200, France
  • Investigator Site
    Bad Nauheim, 61231, Germany
  • Investigator Site
    Berlin, 10117, Germany
  • Investigator Site
    Cologne, 50937, Germany
  • Investigator Site
    Erlangen, 91054, Germany
  • Investigator Site
    Magdeburg, 39120, Germany
  • Investigator Site
    Mainz, 55131, Germany
  • Investigator Site
    Bath, BA11RL, United Kingdom
  • Investigator Site
    Leeds, LS74SA, United Kingdom
  • Investigator Site
    Liverpool, L97AL, United Kingdom
  • Investigator Site
    London, NW32QG, United Kingdom
  • Investigator Site
    Salford, M55AP, United Kingdom
08

References and documents

Publications

  • Denton CP, Hachulla E, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242. PubMed 29193819 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Apr 2015, 5 months.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2014
First posted
Oct 9, 2014
StartActual
Oct 31, 2014
Primary completionActual
Apr 30, 2015
CompletionActual
Jun 30, 2015
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02260557
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Oct 31, 2014
Primary completion
Apr 30, 2015
Completion
Jun 30, 2015
Last update
Jun 3, 2026

Study contacts

Ralph Preiss, MD
study chair · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion